[ORGANIZATION]
Sociedade Brasileira de Endocrinologia e Metabologia
Featured in 6 tracked stories · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
291 clusters · 1104 sources · last updated
Latest: Novo Nordisk faces lawsuits over Ozempic and NAION risks
Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr
Brazil plans semaglutide integration into SUS
8 clusters · 117 sources · last updated
Latest: GLP-1 weight loss drug prescriptions surge 304.9% in Brazil
The Brazilian Ministry of Health is progressing with plans to incorporate semaglutide-based weight-loss medications into the Unified Health System (SUS). On September 24, 2026, the Ministry submitted a formal request to
Body image and GLP-1 medication trends in Brazil
6 clusters · 91 sources · last updated
Latest: Health experts warn against risks of rapid weight loss
Health experts and regulatory bodies in Brazil continue to intensify warnings regarding the use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight loss. While effective for obesity, a systematic
Brazil thyroid health guidelines during pregnancy
2 clusters · 18 sources · last updated
Latest: Thyroid health and iodine use during pregnancy
Medical guidelines and nutritional considerations regarding thyroid health during pregnancy in Brazil have been clarified. The Brazilian Society of Endocrinology and Metabology (SBEM) and the Brazilian Federation of Gy